Hansoh Pharmaceutical Group launched on Thursday Hong Kong’s second-largest initial public offering this year, looking for as much as HK$7.8 billion $1 billion as the Chinese generic drug manufacturer tries to draw investor attention away from a focus on biotech companies.
Hansoh’s Reg S144A deal features 551.3 million new shares, equivalent to 9.7% of the company’s enlarged share capital, and a greenshoe option of 82.6 million shares. The shares are being offered at HK$13.06 to HK$14.26 each, according to a deal termsheet.
Around 93% of the shares will be offered to institutional investors, while the rest will be offered to the public, subject...
¬ Haymarket Media Limited. All rights reserved.
